#chronic-coronary-disease #secondary-prevention #coronary-artery-disease #angina #revascularization #guidelines

Chronic Coronary Disease (CCD)

Details of the Concept

Chronic coronary disease (CCD) is an umbrella term for stable outpatient presentations of coronary artery disease. It encompasses patients post-ACS/revascularisation once stabilised, those with ischaemic cardiomyopathy, stable angina syndromes managed medically, coronary vasospasm or microvascular angina (INOCA), and coronary disease detected incidentally on screening. CCD represents a clinical continuum from the acute phase of ACS into long-term outpatient management. Approximately 20.1 million Americans have CCD; it remains the leading cause of death in the US and worldwide despite an ~25% relative decline in CHD death over the past decade.

Key Facts

Epidemiology

~20.1 million persons in the US have CCD; 11.1 million have chronic stable angina; 8.8 million have had a prior MI (sources/CCS-AHA-2023, rating: very high)
25% of all MIs in the US (~200,000 annually) occur in persons with prior MI — "recurrent MI" population (sources/CCS-AHA-2023, rating: very high)
Prevalence varies by age, sex, race, ethnicity, and geography; NH Black women have CHD prevalence 7.2% — higher than NH White women (6.0%) (sources/CCS-AHA-2023, rating: very high)
Social determinants of health (SDOH) — health care access, economic stability, neighbourhood environment — are key drivers of outcomes in CCD and must be systematically assessed (sources/CCS-AHA-2023, rating: very high)

Risk Stratification

Integrate results of noninvasive/invasive testing with clinical, social, and demographic variables using validated risk models (sources/CCS-AHA-2023, rating: very high)
Three annual risk categories for CV death or nonfatal MI: low (<1%), intermediate (1–3%), high (>3%)
Routine ICA for asymptomatic stable patients not recommended — COR 3 No Benefit/A (COURAGE, BARI-2D, ISCHEMIA) (sources/CCS-AHA-2023, rating: very high)
Functional testing recommended for patients with change in symptoms/functional status despite GDMT — COR 1/B-NR (sources/CCS-AHA-2023, rating: very high)

Beta Blockers — Paradigm Change

COR 1/A: LVEF ≤40% with or without prior MI — reduces future MACE and CV death; metoprolol succinate, carvedilol, or bisoprolol preferred (sources/CCS-AHA-2023, rating: very high)
COR 2b/B-NR: Prior MI, LVEF >50%, ≤1 year — reasonable to reassess need for long-term (>1 year) beta blocker if no angina, arrhythmia, or uncontrolled hypertension (sources/CCS-AHA-2023, rating: very high)
COR 3 No Benefit/B-NR: No prior MI, LVEF >50%, no other indication — beta blockers do NOT reduce MACE in this population; REACH registry, NCDR CathPCI, and CHARISMA post-hoc analysis consistently negative (sources/CCS-AHA-2023, rating: very high)
SMART-DECISION 2026 (RCT evidence update): In stable post-MI patients with LVEF ≥40% and no HF who had already received ≥1 year of beta-blocker therapy (median 4.7 years post-MI), discontinuation was noninferior to continuation for composite of all-cause death, recurrent MI, and HF hospitalisation (HR 0.80; 95% CI 0.57–1.13; upper CI 1.13 < NI margin 1.4; P=0.001 for NI). No differences in LVEF, quality of life, or serious adverse events. Provides first large RCT evidence that BB withdrawal is safe in this stabilised population. See concepts/Beta-Blocker-Post-MI for full evidence synthesis. (sources/BB-SMARTDECISION-NEJM-2026, rating: very high)

Guideline-Directed Medical Therapy (GDMT) Highlights

High-intensity statin COR 1/A: ≥50% LDL-C reduction; generic formulations are cost-saving; monitor at 4–12 weeks then 3–12 monthly (sources/CCS-AHA-2023, rating: very high)
Ezetimibe (COR 2a) + PCSK9 mAb (COR 2a/A) for very high risk (LDL ≥70 on max statin ± ezetimibe): see concepts/Dyslipidemia-Management (sources/CCS-AHA-2023, rating: very high)
SGLT2i + GLP-1 RA COR 1/A for CCD + T2DM: SGLT2i primarily reduces HF/CKD progression; GLP-1 RA primarily reduces atherosclerotic events; dual therapy may be additive (sources/CCS-AHA-2023, rating: very high)
SGLT2i COR 1/A for HFrEF (LVEF ≤40%) regardless of DM; COR 2a/B-R for HFpEF (sources/CCS-AHA-2023, rating: very high)
BP target <130/<80 mmHg COR 1/B-R: ACEi/ARB or beta blocker first-line for compelling indications (recent MI, angina, LVEF ≤40%) (sources/CCS-AHA-2023, rating: very high)
ACEi/ARB COR 1/A: HTN + DM + LVEF ≤40% + CKD; COR 2b/B-R without these comorbidities (sources/CCS-AHA-2023, rating: very high)

Antiplatelet Strategy in Chronic CCD

Aspirin 81 mg daily COR 1/A: Secondary prevention — 81 mg non-inferior to 325 mg with fewer bleeds (ADAPTABLE trial) (sources/CCS-AHA-2023, rating: very high)
DAPT 6 months post-PCI → SAPT COR 1/A: Meta-analysis (n=31,666): similar MACE, lower bleeding vs 12-month DAPT; aspirin continued indefinitely (sources/CCS-AHA-2023, rating: very high)
P2Y12 monotherapy after 1–3 months DAPT COR 2a/A: SMART CHOICE, STOP-DAPT2, TWILIGHT, GLOBAL LEADERS — reduced bleeding without increased ischaemic events (sources/CCS-AHA-2023, rating: very high)
Extended DAPT >12 months (up to 3 years) for prior MI + low bleeding COR 2b/A: PEGASUS-TIMI 54 — ticagrelor 60 mg BID: 16% reduction in CV death/MI/stroke; NNT ~91; increased major bleeding (sources/CCS-AHA-2023, rating: very high)
Low-dose rivaroxaban 2.5 mg BID + aspirin COR 2a/B-R: High ischaemic risk, low-moderate bleeding, no OAC/DAPT indication — COMPASS trial: composite CV death/stroke/MI 4.1% vs 5.4%; major bleeding higher (3.1% vs 1.9%) (sources/CCS-AHA-2023, rating: very high)
See concepts/DAPT-Strategies for full antiplatelet strategy details (sources/CCS-AHA-2023, rating: very high)
DOAC monotherapy in CCD + AF beyond the early period: May be considered after 1 year post-PCI (COR 2b/C-LD based on AFIRE). EPIC-CAD (NEJM 2024) now provides the largest standard-dose DOAC RCT evidence: edoxaban monotherapy vs edoxaban + antiplatelet — NACE HR 0.44 (P<0.001), bleeding HR 0.34, ischemic events NS (underpowered). See concepts/AF-Stable-CAD-Antithrombotic. (sources/edoxaban-af-cad-nejm-2024, rating: high)

Colchicine

COR 2b/B-R: 0.5 mg daily for secondary prevention of recurrent ASCVD events
LoDoCo2 (stable ASCVD): 6.8% vs 9.6% primary MACE (P<0.001); trend toward excess noncardiovascular death in colchicine group
COLCOT (post-ACS): 5.5% vs 7.1% primary MACE (P=0.02) — primarily stroke and urgent revascularisation
Avoid: eGFR <30 mL/min/m²; CYP3A4 interactions; use in highest remaining-risk patients only (sources/CCS-AHA-2023, rating: very high)
CLEAR (NEJM 2025; n=7,062; largest post-MI colchicine RCT; 649 events): Colchicine 0.5 mg/day for median 3 years — no MACE benefit (HR 0.99; 95% CI 0.85–1.16; P=0.93). CRP confirmed reduced (biological effect); no excess infections. Joins CHANCE-3 and CONVINCE as three recent neutral trials. ESC Class IIa and FDA approval for colchicine in CAD both pre-date CLEAR — guideline re-evaluation anticipated. See concepts/Colchicine-in-Cardiovascular-Disease. (sources/colchicine-ami-clear-nejm-2025, rating: very high)

Antianginal Therapy

First-line COR 1/B-R: Beta blocker OR CCB OR long-acting nitrate — equal evidence for angina relief; no difference in mortality
Combination COR 1/B-R: Add second agent from different class if persistent angina
Ranolazine COR 1/B-R: If angina persists on beta blocker/CCB/nitrate (CARISA, ERICA trials)
Ivabradine COR 3 Harm: In CCD with normal LV function — BEAUTIFUL trial: 7.6% vs 6.5% primary endpoint (CV death/MI; P=0.02); harm signal (sources/CCS-AHA-2023, rating: very high)

Revascularisation — The ISCHEMIA Paradigm

Stable CCD without severe LV dysfunction or left main disease: No survival benefit from routine revascularisation — COURAGE, BARI-2D, ISCHEMIA all confirm null effect on all-cause death and MACE at 3–4 years; ISCHEMIA 7-year: late CV mortality benefit in invasive arm (sources/CCS-AHA-2023, rating: very high)
Revascularisation COR 1/A for lifestyle-limiting angina despite GDMT — symptom improvement confirmed (ISCHEMIA: higher Seattle Angina Questionnaire scores sustained ×36 months in invasive arm, greatest in daily/weekly angina at baseline) (sources/CCS-AHA-2023, rating: very high)
CABG for LV dysfunction (LVEF ≤35%) — COR 1/B-R: STICH trial (n=1,212): CABG + medical therapy — lower CV death (28% vs 33%; P=0.05) and all-cause death at 10 years vs medical therapy alone (sources/CCS-AHA-2023, rating: very high)
PCI for LVEF ≤35% — no survival benefit: REVIVED-BCIS2 (n=700, LVEF ≤35%): PCI + GDMT vs GDMT alone — no difference in all-cause death or HF hospitalisation at 3.4 years (sources/CCS-AHA-2023, rating: very high)
CABG preferred over PCI for: (1) Left main + SYNTAX >33 (COR 1/B-R); (2) Multivessel + SYNTAX >33 (COR 2a/B-R); (3) Diabetes + multivessel + LAD involvement (COR 1/A; FREEDOM: HR 1.36 for PCI at 8 years) (sources/CCS-AHA-2023, rating: very high)
FFR/iFR before PCI for intermediate stenoses — COR 1/A: FAME-2: FFR-guided PCI superior to medical therapy for urgent revascularisation reduction, sustained ×5 years; high economic value (<$50K/QALY) (sources/CCS-AHA-2023, rating: very high)
Heart Team required COR 1/B-NR: Complex 3-vessel or left main disease (sources/CCS-AHA-2023, rating: very high)

Intracoronary Imaging Guidance for PCI (2026 Update)

Guideline position (pre-2026): 2024 ESC and 2025 ACC/AHA guidelines recommend IVUS or OCT as Class IA for complex and left main PCI — based primarily on Asian RCT evidence (RENOVATE-COMPLEX-PCI, ULTIMATE, IVUS-XPL) and observational data (sources/ACS-AHA-2025, rating: very high)
IVUS-CHIP (NEJM 2026, N=2020): Routine IVUS-guided complex high-risk PCI at 37 European centres was NOT superior to angiography-guided PCI for TVF (13.9% vs 11.1%; HR 1.25; P=0.08). Stent-optimisation criteria met in only 48% of IVUS-guided lesions due to high calcification burden (42.2% severe calcification). Stent thrombosis lower in IVUS arm (0.2% vs 1.0%; HR 0.20). See concepts/Intracoronary-Imaging-Guided-PCI. (sources/ivus-chip-nejm-2026, rating: high)
IVUS-OPTIMAL (NEJM 2026, N=806): IVUS-guided PCI for unprotected left main coronary artery disease at 28 European centres was NOT superior to angiography-guided PCI for patient-oriented composite (33.7% vs 30.9%; HR 1.11; P=0.40). No difference across any secondary endpoint. See entities/Left-Main-Coronary-Disease and concepts/Intracoronary-Imaging-Guided-PCI. (sources/ivus-optimal-nejm-2026, rating: high)
Possible explanation for neutral results in both 2026 trials: experienced European operators at high-volume centres may have internalised IVUS-derived sizing and optimisation principles into angiography-guided practice, reducing the performance gap

INOCA (Ischaemia with Nonobstructive Coronary Arteries)

50% of patients undergoing elective coronary angiography have nonobstructive CAD; associated with increased death and MI risk (sources/CCS-AHA-2023, rating: very high)
COR 2a/B-R: Invasive coronary physiology-guided stratified medical therapy — CorMicA trial: +11.7 units Seattle Angina Questionnaire at 6 months vs standard care
Endotypes: microvascular angina (IMR ≥25, CFR <2.0); vasospastic angina (>90% epicardial constriction with acetylcholine); mixed; noncardiac
Endotype-specific therapy: microvascular → beta blocker first, then CCB, then ranolazine; vasospastic → CCB first, then long-acting nitrate (sources/CCS-AHA-2023, rating: very high)

Spontaneous Coronary Artery Dissection (SCAD)

Underrecognised cause of MI; more common in young women with low classical ASCVD risk; recurrence up to 27% at 5 years (sources/CCS-AHA-2023, rating: very high)
Conservative management preferred acutely; CR COR 1/C-LD; beta blockers COR 2b/C-LD (64% reduction in recurrent SCAD in observational study)
Screen for fibromuscular dysplasia and extracoronary arteriopathies — COR 2a/C-LD (sources/CCS-AHA-2023, rating: very high)

Contradictions / Open Questions

Beta-blocker de-escalation — partially resolved by SMART-DECISION 2026: The 2023 CCD guideline flagged this as an evidence gap with multiple RCTs pending. SMART-DECISION (n=2540, NEJM 2026) now provides RCT evidence that discontinuation is noninferior to continuation in stable LVEF ≥40%, no-HF patients ≥1 year post-MI. Remaining open questions: (1) safe timing of discontinuation earlier than 4.7 years post-MI; (2) LVEF 40–49% subgroup — insufficient data; (3) generalisability beyond Korean populations; (4) wide NI margin (1.4) means small risk increases cannot be excluded. Guideline recommendation may be upgraded in future revision. (sources/BB-SMARTDECISION-NEJM-2026, rating: very high; sources/CCS-AHA-2023, rating: very high)
Colchicine: positive LoDoCo2/COLCOT vs neutral CLEAR/CHANCE-3/CONVINCE — net benefit now uncertain: LoDoCo2 (stable CAD; 31% RRR) and COLCOT (post-MI; 23% RRR) supported colchicine and led to ESC Class IIa and FDA approval. CLEAR (NEJM 2025; n=7,062; 649 events; HR 0.99; P=0.93), CHANCE-3 (ischemic stroke; neutral), and CONVINCE (ischemic stroke; neutral) are three subsequent large RCTs showing no MACE reduction. CLEAR is the largest and most recent post-MI trial. The non-cardiovascular death signal from COPS was not replicated in COLCOT, LoDoCo2, or CLEAR; CLEAR showed numerically lower non-CV deaths in the colchicine arm. A guideline re-evaluation is anticipated; colchicine benefit in stable and acute coronary disease is now uncertain when the full trial evidence is considered. See concepts/Colchicine-in-Cardiovascular-Disease. (sources/colchicine-ami-clear-nejm-2025, rating: very high; sources/CCS-AHA-2023, rating: very high)
ISCHEMIA late benefit discordance: No MACE benefit at 3–4 years; but CV mortality reduction at 7 years in invasive arm. Whether this represents a late protective effect or statistical fluctuation is unresolved. (sources/CCS-AHA-2023, rating: very high)
Icosapent ethyl REDUCE-IT mineral oil placebo controversy: Consistent with concepts/Dyslipidemia-Management contradiction — ACC/AHA 2023 CCD gives only COR 2b; REDUCE-IT mineral oil may have inflated benefit estimate. (sources/CCS-AHA-2023, rating: very high)
Inclisiran MACE data: Bempedoic acid and inclisiran listed as COR 2b options — CLEAR Outcomes (bempedoic acid MACE reduction 13%) published after guideline; inclisiran CVOT still ongoing. Future guideline update may upgrade bempedoic acid to COR 2a or higher. (sources/CCS-AHA-2023, rating: very high)
OAC monotherapy in stable CCD + AF — AFIRE vs EPIC-CAD vs guideline COR discordance: AFIRE (2019) showed rivaroxaban monotherapy noninferior to combination in stable CCD + AF; CCC-AHA 2023 gives this COR 2b/C-LD. EPIC-CAD (2024) now provides the largest and most methodologically rigorous RCT evidence with standard-dose edoxaban (NACE HR 0.44; NNT 10.6; ischemic events NS but underpowered; bleeding HR 0.34). Both trials support OAC monotherapy but neither was powered for ischemic events — a small residual ischemic risk from removing antiplatelet cannot be excluded. EPIC-CAD is East Asian only, potentially limiting generalizability to Western populations with different bleeding propensity. Guideline upgrade to COR 2a or higher is anticipated. See concepts/AF-Stable-CAD-Antithrombotic. (sources/edoxaban-af-cad-nejm-2024, rating: high; sources/CCS-AHA-2023, rating: very high)
IVUS Class IA recommendation vs 2026 European RCTs: Both 2024 ESC and 2025 ACC/AHA guidelines give Class IA to IVUS/OCT for complex and left main PCI. Both IVUS-CHIP (complex PCI; N=2020; NEJM 2026) and IVUS-OPTIMAL (left main PCI; N=806; NEJM 2026) failed to show superiority of IVUS guidance over expert angiography-guided PCI at high-volume European centres. These are the most direct contradictions yet to the Class IA recommendation; guideline revision is anticipated. Whether the neutral results reflect European operator expertise or a genuine absence of benefit requires further investigation. (sources/ivus-chip-nejm-2026, rating: high; sources/ivus-optimal-nejm-2026, rating: high; sources/ACS-AHA-2025, rating: very high)

Connections

Related to entities/Acute-Coronary-Syndrome — CCD is the chronic phase of ACS; same patient continuum
Related to concepts/DAPT-Strategies — antiplatelet management for both acute and chronic coronary phases
Related to concepts/Dyslipidemia-Management — very high risk definition; stepwise LDL-C lowering
Related to entities/Heart-Failure — ischaemic cardiomyopathy; CABG/SGLT2i/beta-blocker management
Related to entities/Atrial-Fibrillation — anticoagulation in CCD + AF; AFIRE trial; EPIC-CAD
Related to concepts/AF-Stable-CAD-Antithrombotic — OAC monotherapy evidence in stable CCD + AF
Related to concepts/ASCVD-Risk-Assessment — PREVENT model; risk-guided therapy
Related to concepts/Right-Heart-Catheterization — haemodynamic assessment in INOCA and ischaemic HF
Related to concepts/Beta-Blocker-Post-MI — full post-MI beta-blocker evidence synthesis
Related to concepts/Intracoronary-Imaging-Guided-PCI — IVUS vs angiography guidance for complex and left main PCI
Related to entities/Left-Main-Coronary-Disease — LMCA disease management and OPTIMAL trial
Related to concepts/Colchicine-in-Cardiovascular-Disease — colchicine in stable ASCVD; CLEAR null result challenges COR 2b basis